PlainPharmaWatch

CMS Open Payments · Program Year 2024

Otsuka Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Co., Ltd. reported $2,478,267.34 across General Payments, Research, and Ownership to 193 physicians and teaching hospitals across 213 transactions.

See the rankings → How this is sourced
$2.5M
All-tracks total
213
Transactions
193
Recipients
−$228.3K
General Payments vs PY2023

Otsuka Pharmaceutical Co., Ltd. reported $2,478,267.34 across all CMS Open Payments tracks (General + Research + Ownership) to 193 physicians and teaching hospitals in Program Year 2024 - ranking #406 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $357,128.90, averaging $12.8K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer otsuka-pharmaceutical-co-ltd Otsuka Pharmaceutical Co., Ltd.

$2.5M · #406/1,925 · 0.0% industry · PY2024

  • TOT $2.5M
  • RANK #406
  • SHARE 0.0%
  • TXN 213
  • RCP 193
  • CAT 5
  • GEN $357.1K
  • ΔGEN −$228.3K
  • TOP1 23.8%
  • PY 2024

Volume peers

Nearest volume peer: CoapTech, Inc. ($2.5M)

Centerline Biomedical Inc.$2.5MMED-EL Corporation$2.5MTolmar, Inc.$2.5MCoapTech, Inc.$2.5MOtsuka Pharmaceutical Co., L…$2.5M
All-tracks payment totals near Otsuka Pharmaceutical Co., Ltd. (CMS Open Payments PY2024)

Otsuka Pharmaceutical Co., Ltd. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Otsuka Pharmaceutical Co., Ltd.'s CMS-reported General Payments decreased by $228.3K (−39.0%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: OTSUKA PHARMACEUTICAL CO., LTD.PY2023: OTSUKA PHARMACEUTICAL CO., LTD.PY2024: Otsuka Pharmaceutical Co., Ltd.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$585.5KPY2024$357.1K
PY2023
$585,468.87
PY2024
$357,128.90

What the Data Shows for Otsuka Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Co., Ltd. ranks #406 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $2,478,267.34 across 213 transactions to 193 physicians and teaching hospitals - $11.6K per transaction and $12.8K per recipient on average.

101 transactions worth $109.5K make "Travel and Lodging" the top general-payment category in the 5-category breakdown below, 30.7% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Otsuka Pharmaceutical Co., Ltd. made 5 types of general payments. "Travel and Lodging" is the largest category at $109.5K, 30.7% of General Payments.

Otsuka Pharmaceutical Co., Ltd. reports 5 general-payment categories - the top three are Travel and Lodging (30.7%), Royalty or License (29.4%), and Compensation for Services Other Than Consulting (24.5%). The remaining 2 categories make up 15.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Otsuka Pharmaceutical Co., Ltd. divides its payments

How the reported total splits across payment categories

1. Travel and Lodging$109.5K2. Royalty or License$105.0K3. Compensation for Services…$87.4K4. Consulting Fee$52.6K5. Food and Beverage$2.6K
Payment Type Amount Transactions
Travel and Lodging $109.5K 101
Royalty or License $105.0K 2
Compensation for Services Other Than Consulting $87.4K 14
Consulting Fee $52.6K 26
Food and Beverage $2.6K 50

Recipient Concentration in General Payments

The five largest recipient relationships account for $248,988.21 (69.7%) of $357,128.90 in this company's General Payments records across 28 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Otsuka Pharmaceutical Co., Ltd.

The five named recipients with the highest reported General Payments from this company

Cleveland Clinic Hospital$85.0KGeorge Grossberg$82.1KMichael Thase$33.9KChristoph Correll$28.0KChildrens Hospital Corporati…$20.0K
  1. 1

    Cleveland Clinic Hospital

    $85,000.00 across 1 reported transactions

  2. 2

    George Grossberg

    $82,078.80 across 45 reported transactions

  3. 3

    Michael Thase

    $33,916.34 across 22 reported transactions

  4. 4

    Christoph Correll

    $27,993.07 across 37 reported transactions

  5. 5

    Childrens Hospital Corporation

    $20,000.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Otsuka Pharmaceutical Co., Ltd.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Otsuka Pharmaceutical Co., Ltd..

Orpyx Medical Technologies US Inc.

HHI 1372

NuSmile, Ltd.

HHI 1377

Fusion Orthopedics, LLC.

HHI 1377

Helsinn Therapeutics (U.S.), Inc.

HHI 1382

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Otsuka Pharmaceutical Co., Ltd..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Otsuka Pharmaceutical Co., Ltd.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.